サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1777871

血液がん診断の世界市場

Blood Cancer Diagnostics

出版日
ページ情報
英文 372 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
血液がん診断の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 372 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血液がん診断の世界市場は2030年までに米国で144億米ドルに達する見込み

2024年に105億米ドルと推定される血液がん診断の世界市場は、2024年から2030年にかけてCAGR 5.4%で成長し、2030年には144億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである機器は、CAGR 6.6%を記録し、分析期間終了までに84億米ドルに達すると予測されます。アッセイキットと試薬セグメントの成長率は、分析期間中CAGR 3.9％と推定されます。

米国市場は29億米ドル、中国はCAGR 8.8％で成長すると推定・予測

米国の血液がん診断市場は2024年に29億米ドルと推定されます。世界第2位の経済大国である中国は、2024～2030年の分析期間においてCAGR 8.8％をたどり、2030年までに29億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.4％と予測されています。欧州では、ドイツがCAGR 3.5%で成長すると予測されています。

世界の血液がん診断市場- 主要動向と促進要因のまとめ

血液がん診断ががん領域で重要な焦点になりつつあるのはなぜか？

血液がん診断は、白血病、リンパ腫、多発性骨髄腫などの血液悪性腫瘍の早期発見、疾患分類、個別化治療計画を可能にし、現代の腫瘍学にとって不可欠な要素となっています。血液がんの世界の負担が増加の一途をたどる中、ヘルスケアプロバイダーは生存率と治療成績を改善するために診断技術の進歩を優先しています。血液がんは世界的にがん関連死亡の大部分を占めており、タイムリーな介入には早期かつ正確な発見が不可欠です。

精密医療と標的療法の出現により、高感度診断ツールに対する需要が急増しています。全血球算定（CBC）、骨髄生検、フローサイトメトリーなどの従来の診断法は、現在、先進的な分子・遺伝子検査で補完されつつあります。次世代シーケンシング（NGS）、リキッドバイオプシー、人工知能（AI）主導の診断アルゴリズムの統合は、血液がん発見に革命をもたらし、早期診断とより個別化された治療戦略を可能にしています。ヘルスケア産業が非侵襲的で高精度の診断ソリューションに移行するにつれ、血液がん診断市場は急成長が見込まれています。

技術の進歩は血液がん診断をどのように変化させているか？

分子診断学、バイオインフォマティクス、デジタル病理学における著しい進歩は、血液がん診断の展望を再構築し、より速く、より正確で、より侵襲性の低い検出方法を可能にしています。この分野で最も革新的なイノベーションの一つがリキッドバイオプシーであり、血液サンプルから循環腫瘍DNA（ctDNA）やその他のバイオマーカーを検出することができます。従来の骨髄生検とは異なり、リキッドバイオプシーは、最小残存病変（MRD）を検出し、治療反応をリアルタイムでモニターできる非侵襲的な代替法を提供します。この技術は、疾患の進行が継続的なモニタリングを必要とする白血病やリンパ腫の患者にとって特に有益です。

血液がん診断におけるもう一つの大きなブレークスルーは、次世代シークエンシング（NGS）とポリメラーゼ連鎖反応（PCR）ベースの技術が広く採用されていることです。これらの分子ツールは包括的な遺伝子プロファイリングを可能にし、腫瘍医が様々なタイプの血液がんに関連する特定の変異や遺伝子異常を特定することを可能にします。AIを駆使した診断アルゴリズムも血液病理学的解析の精度を高めており、血液塗抹標本や骨髄吸引液の画像認識を自動化し、異常な細胞形態を高い精度で検出しています。さらに、フローサイトメトリーやイムノフェノタイピングの進歩により、白血病やリンパ腫の異なるサブタイプを区別する能力が向上し、より的を絞った治療アプローチが容易になりつつあります。これらの技術革新が進化を続けるにつれて、早期診断の改善、誤診率の低下、血液腫瘍学における患者管理全般の強化が期待されます。

血液がん診断の成長を牽引する市場動向は？

個別化医療や標的療法の採用が増加していることは、先進的な血液がん診断の需要を煽っている最も重要な動向の一つです。特定の遺伝子変異をターゲットとするがん治療が増加する中、包括的な分子検査は治療の意思決定において重要なステップとなっています。この動向はコンパニオン診断の急速な拡大につながっており、血液がん患者は遺伝子検査を受けて、チロシンキナーゼ阻害剤（TKI）やモノクローナル抗体などの標的治療の適格性を判断します。

市場を形成するもう一つの主要動向は、がん診断における人工知能と自動化への依存の高まりです。AIを搭載した画像解析ツールは血液病理学ワークフローを合理化し、診断に要する時間を短縮すると同時に精度を向上させています。さらに、分散型検査やポイントオブケア診断の拡大により、特にヘルスケアインフラが限られている地域では、血液がんの検出がより身近なものとなっています。クラウドベースの診断プラットフォームと遠隔医療ソリューションの統合は、遠隔診断と患者モニタリングをさらに強化し、腫瘍医がより効率的に疾患の進行を追跡できるようにしています。世界のヘルスケア情勢ががんの早期発見と予防検診にシフトする中、革新的な血液がん診断に対する需要は高まることが予想されます。

血液がん診断市場の将来を形作る主な成長促進要因とは？

血液がん診断市場の成長は、がん罹患率の上昇、診断技術の進歩、精密腫瘍学への投資の増加など、複数の要因によってもたらされます。最も重要な要因の1つは、血液悪性腫瘍の罹患率の増加であり、これにより早期かつ正確な診断ソリューションに対する需要が高まっています。白血病リンパ腫協会によると、血液がんは全世界のがん診断の10％近くを占めており、発見と患者の転帰を改善するための強固な診断インフラの必要性が浮き彫りになっています。

市場を形成するもう一つの重要な促進要因は、リキッドバイオプシーと低侵襲診断技術への注目の高まりです。ヘルスケアプロバイダーと患者が従来の侵襲的な処置に代わるものを求める中、リキッド生検は血液がんの検出とモニタリングにおけるゲームチェンジャーとして台頭してきました。さらに、政府の取り組みやがん研究への資金援助が新規診断プラットフォームの開発を加速させており、市場機会はさらに拡大しています。バイオマーカー主導の臨床試験や先進的診断薬に対する規制当局の承認の高まりも成長を後押ししており、製薬会社は診断薬企業と共同で新たな治療法のコンパニオンテストを開発しています。

血液腫瘍学が進歩し続ける中、AI、ビッグデータ解析、分子診断学の統合が血液がん診断の将来を形作る上で極めて重要な役割を果たすと思われます。精密診断の利用可能性の向上は、早期発見と治療モニタリングにおける継続的な技術革新と相まって、この市場の大きな成長を促し、最終的には世界中の血液がん患者の生存率と生活の質を向上させると思われます。

セグメント

製品タイプ（装置、アッセイキット、試薬）、検査タイプ（血液検査、画像検査、生検、分子検査）、エンドユーザー（病院・診療所エンドユーザー、診断ラボエンドユーザー、調査機関エンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • Alercell, Inc.
  • Asuragen（a Bio-Techne brand）
  • Becton, Dickinson and Company（BD）
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GE HealthCare Technologies Inc.
  • Grail, Inc.
  • Guardant Health, Inc.
  • HORIBA, Ltd.
  • Illumina, Inc.
  • InVivoScribe, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics
  • SkylineDx
  • Sophia Genetics
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29643

Global Blood Cancer Diagnostics Market to Reach US$14.4 Billion by 2030

The global market for Blood Cancer Diagnostics estimated at US$10.5 Billion in the year 2024, is expected to reach US$14.4 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Assay Kits and Reagents segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 8.8% CAGR

The Blood Cancer Diagnostics market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Blood Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Is Blood Cancer Diagnostics Becoming a Critical Focus in Oncology?

Blood cancer diagnostics have become an essential component of modern oncology, enabling early detection, disease classification, and personalized treatment planning for hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. As the global burden of blood cancers continues to rise, healthcare providers are prioritizing advancements in diagnostic technologies to improve survival rates and treatment outcomes. Blood cancers account for a significant portion of cancer-related deaths worldwide, making early and accurate detection crucial for timely intervention.

With the emergence of precision medicine and targeted therapies, the demand for high-sensitivity diagnostic tools has surged. Traditional diagnostic methods, including complete blood counts (CBC), bone marrow biopsies, and flow cytometry, are now being supplemented with advanced molecular and genetic testing. The integration of next-generation sequencing (NGS), liquid biopsy, and artificial intelligence (AI)-driven diagnostic algorithms is revolutionizing blood cancer detection, allowing for earlier diagnosis and more personalized treatment strategies. As the healthcare industry moves toward non-invasive, highly accurate diagnostic solutions, the market for blood cancer diagnostics is expected to grow rapidly.

How Are Technological Advancements Transforming Blood Cancer Diagnostics?

Significant advancements in molecular diagnostics, bioinformatics, and digital pathology are reshaping the landscape of blood cancer diagnostics, enabling faster, more precise, and less invasive detection methods. One of the most transformative innovations in this space is liquid biopsy, which allows for the detection of circulating tumor DNA (ctDNA) and other biomarkers in blood samples. Unlike traditional bone marrow biopsies, liquid biopsy offers a non-invasive alternative that can detect minimal residual disease (MRD) and monitor treatment response in real-time. This technology is particularly beneficial for patients with leukemia and lymphoma, where disease progression requires continuous monitoring.

Another major breakthrough in blood cancer diagnostics is the widespread adoption of next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based techniques. These molecular tools enable comprehensive genetic profiling, allowing oncologists to identify specific mutations and genetic aberrations associated with different types of blood cancer. AI-powered diagnostic algorithms are also enhancing the accuracy of hematopathology analysis, automating image recognition in blood smears and bone marrow aspirates to detect abnormal cell morphology with high precision. Furthermore, advancements in flow cytometry and immunophenotyping are improving the ability to distinguish between different subtypes of leukemia and lymphoma, facilitating more targeted treatment approaches. As these technological innovations continue to evolve, they are expected to improve early diagnosis, reduce misdiagnosis rates, and enhance overall patient management in hematologic oncology.

Which Market Trends Are Driving Growth in Blood Cancer Diagnostics?

The growing adoption of personalized medicine and targeted therapies is one of the most significant trends fueling the demand for advanced blood cancer diagnostics. With an increasing number of cancer treatments being designed to target specific genetic mutations, comprehensive molecular testing has become a critical step in treatment decision-making. This trend has led to the rapid expansion of companion diagnostics, where blood cancer patients undergo genetic testing to determine their eligibility for targeted therapies, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies.

Another key trend shaping the market is the increasing reliance on artificial intelligence and automation in cancer diagnostics. AI-powered image analysis tools are streamlining hematopathology workflows, reducing the time required for diagnosis while improving accuracy. Additionally, the expansion of decentralized testing and point-of-care diagnostics is making blood cancer detection more accessible, particularly in regions with limited healthcare infrastructure. The integration of cloud-based diagnostic platforms and telemedicine solutions is further enhancing remote diagnosis and patient monitoring, allowing oncologists to track disease progression more efficiently. As the global healthcare landscape shifts toward early cancer detection and preventive screening, the demand for innovative blood cancer diagnostics is expected to rise.

What Are the Key Growth Drivers Shaping the Future of the Blood Cancer Diagnostics Market?

The growth in the blood cancer diagnostics market is driven by multiple factors, including rising cancer prevalence, advancements in diagnostic technology, and increasing investments in precision oncology. One of the most significant drivers is the growing incidence of hematologic malignancies, which has led to a higher demand for early and accurate diagnostic solutions. According to the Leukemia & Lymphoma Society, blood cancers account for nearly 10% of all cancer diagnoses worldwide, underscoring the need for robust diagnostic infrastructure to improve detection and patient outcomes.

Another crucial driver shaping the market is the increasing focus on liquid biopsy and minimally invasive diagnostic techniques. With healthcare providers and patients seeking alternatives to traditional invasive procedures, liquid biopsy has emerged as a game-changer in blood cancer detection and monitoring. Additionally, government initiatives and funding for cancer research are accelerating the development of novel diagnostic platforms, further expanding market opportunities. The rise of biomarker-driven clinical trials and regulatory approvals for advanced diagnostics is also propelling growth, as pharmaceutical companies collaborate with diagnostic firms to develop companion tests for emerging therapies.

As the field of hematologic oncology continues to advance, the integration of AI, big data analytics, and molecular diagnostics will play a pivotal role in shaping the future of blood cancer diagnostics. The increasing availability of precision diagnostics, coupled with ongoing innovations in early detection and treatment monitoring, will drive significant growth in this market, ultimately improving survival rates and quality of life for blood cancer patients worldwide.

SCOPE OF STUDY:

The report analyzes the Blood Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Instruments, Assay Kits and Reagents); Test Type (Blood Tests, Imaging Tests, Biopsy, Molecular Test); End-Use (Hospitals and Clinics End-Use, Diagnostic Labs End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • Alercell, Inc.
  • Asuragen (a Bio-Techne brand)
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • GE HealthCare Technologies Inc.
  • Grail, Inc.
  • Guardant Health, Inc.
  • HORIBA, Ltd.
  • Illumina, Inc.
  • InVivoScribe, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics
  • SkylineDx
  • Sophia Genetics
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Blood Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Hematologic Malignancies Throws the Spotlight on Early and Accurate Diagnostics
    • Personalized Medicine Paradigm Shift Propels Growth in Precision Diagnostic Technologies
    • Liquid Biopsy Innovations Expand the Addressable Market Opportunity Beyond Traditional Diagnostic Pathways
    • Integration of AI and Machine Learning in Diagnostic Algorithms Strengthens the Business Case for Advanced Screening Tools
    • Next-Generation Sequencing (NGS) Revolution Accelerates Demand for Genomic-Based Blood Cancer Profiling
    • Adoption of Companion Diagnostics Drives Uptake of Targeted Therapies and Diagnostic Platforms
    • Growing Focus on Minimal Residual Disease (MRD) Detection Spurs Development of Ultra-Sensitive Testing Solutions
    • Shift Toward Non-Invasive Diagnostic Modalities Generates New Growth Channels in Early Detection
    • Digital Pathology and Remote Diagnostic Capabilities Sustain Growth in Decentralized Testing Models
    • Heightened Emphasis on Value-Based Care Models Strengthens Demand for Cost-Efficient, High-Impact Diagnostics
    • Laboratory Automation and High-Throughput Testing Platforms Propel Scalability and Market Reach
    • Data-Driven Clinical Decision Support Systems Drive Integration of Diagnostics into Personalized Treatment Pathways
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blood Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blood Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Blood Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Assay Kits and Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Assay Kits and Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Assay Kits and Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Blood Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Blood Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Imaging Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Molecular Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals and Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals and Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals and Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Labs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Diagnostic Labs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Diagnostic Labs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Blood Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Blood Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Blood Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Blood Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • INDIA
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Blood Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Blood Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Blood Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Blood Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
  • AFRICA
    • Blood Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Blood Cancer Diagnostics by Product Type - Instruments and Assay Kits and Reagents Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Blood Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Instruments and Assay Kits and Reagents for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Blood Cancer Diagnostics by Test Type - Blood Tests, Imaging Tests, Biopsy and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Blood Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Blood Tests, Imaging Tests, Biopsy and Molecular Test for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Blood Cancer Diagnostics by End-Use - Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Blood Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics End-Use, Diagnostic Labs End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION